ArticleScientific reports2025
Bone regeneration induced by a novel quercetin/a-CSH/n-HA composite in critical size tibia defect of rats with osteoporosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Bone defects in the presence of osteoporosis present a significant clinical challenge. To address this, we sought to engineer a novel artificial bone substitute exhibiting excellent biocompatibility, osteoconductivity, osteoinduction, anti-aging, and anti-osteoporotic capabilities for enhanced bone regeneration. This project introduces an innovative Q-α-CSH/n-HA composite, synthesized by incorporating Quercetin into alpha-calcium sulfate hemihydrate/nano-hydroxyapatite (α-CSH/n-HA). Q-α-CSH/n-HA composites were fabricated via direct mixing, incorporating Quercetin at concentrations of 0%, 0.5%, 1.5%, and 3%. Physicochemical characteristics were analyzed through Fourier transform infrared spectroscopy (FTIR) and scanning electron microscopy (SEM). The osteoinductive potential and efficacy in promoting bone defect repair were investigated in a critical tibial defect model using 40 one-year-old osteoporotic female SD rats, randomly allocated to four experimental groups. Outcomes, including bone defect repair, material degradation, new bone morphology, and expression of RunX2, OSX, and OCN, were assessed using X-ray, micro-CT, and comprehensive histopathological staining (H&E, Goldner, Safranin O, and immunofluorescence). As the proportion of quercetin increased within the composite, we observed an enrichment in elemental composition and a pronounced elevation in both in vitro and in vivo biological activity of the Q-α-CSH/n-HA complex, despite comparable morphological features as assessed by SEM. Radiographic (X-ray) and micro-CT analyses consistently demonstrated that quercetin-supplemented composite groups significantly enhanced bone defect repair and neobone formation. Complementary histopathological examinations (H&E, Goldner, and Safranin O staining) corroborated these findings, indicating that quercetin significantly augmented new bone generation and accelerated composite biodegradation. Immunofluorescence confirmed that quercetin markedly increased the abundance of RUNX2-, OSX-, and OCN-positive cells. Moreover, CFU assays revealed that the 3% quercetin group yielded significantly superior results compared to the control. The Q-α-CSH/n-HA composite possesses excellent in vitro biocompatibility, osteoconductivity, and osteoinduction. Critically, in vivo studies demonstrated its significant anti-aging, anti-osteoporotic, and overall reparative effects during bone reconstruction. We propose that the mechanism involves a synergistic action between quercetin and calcium ions, which collectively promote the proliferation, migration, recruitment, and osteogenic differentiation of BMSCs. Consequently, the Q-α-CSH/n-HA composite stands as a highly promising artificial bone graft for accelerating bone regeneration, especially pertinent for individuals suffering from osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.